Published in Am J Gastroenterol on April 28, 2009
An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol (2011) 0.88
Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol (2013) 0.87
Fluorescent quantitative PCR of Mycobacterium tuberculosis for differentiating intestinal tuberculosis from Crohn's disease. Braz J Med Biol Res (2014) 0.78
Use of infliximab in pregnancy. Am J Gastroenterol (2010) 0.76
Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease. Case Reports Hepatol (2013) 0.76
Questions regarding use of infliximab and risk of certain viral infections. Am J Gastroenterol (2009) 0.75
The diagnostic value of polymerase chain reaction for Mycobacterium tuberculosis to distinguish intestinal tuberculosis from crohn's disease: A meta-analysis. Saudi J Gastroenterol (2017) 0.75
Catheter-Related Acremonium kiliense Fungemia in a Patient with Ulcerative Colitis under Treatment with Infliximab. Case Rep Infect Dis (2011) 0.75
A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr (2007) 3.91
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2010) 3.32
Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res (2013) 2.84
Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2014) 2.47
Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology (2006) 2.35
Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol (2014) 2.21
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis (2014) 2.17
Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol (2009) 2.14
Different Antibiotic No Culture Eradicating (DANCE) strategy: an easy way to manage H. pylori eradication. Dig Liver Dis (2012) 2.11
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis (2013) 2.03
Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol (2005) 1.82
Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.81
Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol (2010) 1.69
Acute cryptogenic liver failure in an untreated coeliac patient: a case report. Eur J Gastroenterol Hepatol (2005) 1.65
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. Am J Gastroenterol (2006) 1.62
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol (2013) 1.62
The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord (2013) 1.62
Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. Dig Liver Dis (2010) 1.54
Video capsule enteroscopy in the diagnosis of celiac disease: a multicenter study. Am J Gastroenterol (2007) 1.53
Endometriosis, need for a multidisciplinary clinical setting: the internist's point of view. Intern Emerg Med (2010) 1.53
Image-enhanced endoscopy with I-scan technology for the evaluation of duodenal villous patterns. Dig Dis Sci (2012) 1.52
Saccharomyces cerevisiae-associated diarrhea in an immunocompetent patient with ulcerative colitis. J Clin Gastroenterol (2003) 1.48
The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest Endosc (2005) 1.41
Bacillus subtilis isolated from the human gastrointestinal tract. Res Microbiol (2008) 1.38
Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology (2012) 1.35
Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol (2002) 1.32
Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog (2013) 1.19
Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol (2005) 1.18
TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol (2006) 1.17
Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology (2007) 1.17
CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis (2008) 1.15
Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol (2003) 1.15
Extragastric diseases and Helicobacter pylori. Helicobacter (2013) 1.14
Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer (2014) 1.13
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer (2013) 1.12
Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis (2013) 1.12
Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol (2007) 1.12
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2010) 1.11
Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget (2011) 1.11
Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol (2010) 1.11
Faecal calprotectin concentrations in untreated coeliac patients. Scand J Gastroenterol (2007) 1.09
Sequential or combined treatment? That is the question. Radiology (2014) 1.07
Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol (2008) 1.05
Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? Am J Gastroenterol (2009) 1.05
Regional cerebral hypoperfusion in patients with celiac disease. Am J Med (2004) 1.03
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur J Immunol (2011) 1.03
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2011) 1.02
Isolation and characterization of hepatic stem cells, or "oval cells," from rat livers. Methods Mol Biol (2009) 1.02
Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnol (2011) 1.02
Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab (2007) 1.01
Autoimmune enteropathy in children and adults. Scand J Gastroenterol (2009) 1.00
Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohns Colitis (2013) 1.00
Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics (2003) 1.00
Gut microbiota and obesity. Intern Emerg Med (2010) 1.00
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology (2013) 0.99
Extragastric manifestations of Helicobacter pylori infection. Helicobacter (2012) 0.99
Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol (2002) 0.99
The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol (2012) 0.98
The role of methane in intestinal diseases. Am J Gastroenterol (2010) 0.98
Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion (2004) 0.98
Adalimumab in active ulcerative colitis: a "real-life" observational study. Dig Liver Dis (2013) 0.98
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma. Am J Gastroenterol (2009) 0.97
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol (2003) 0.97
Coronary atherosclerotic burden in patients with infection by CagA-positive strains of Helicobacter pylori. Coron Artery Dis (2010) 0.96
Management and treatment of lactose malabsorption. World J Gastroenterol (2006) 0.96
Clinical use of albumin in hepatology. Blood Transfus (2009) 0.96
Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int (2013) 0.95
Colon cancer stem cells: controversies and perspectives. World J Gastroenterol (2013) 0.95
Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des (2013) 0.95
Extragastric manifestations of Helicobacter pylori infection -- other Helicobacters. Helicobacter (2007) 0.95
Helicobacters and extragastric diseases. Helicobacter (2009) 0.95
CagA-positive cytotoxic H. pylori strains as a link between plaque instability and atherosclerotic stroke. Eur Heart J (2004) 0.95
Association between migraine and Celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol (2003) 0.94
The role of H. pylori infection in diabetes. Curr Diabetes Rev (2005) 0.94
Ipilimumab Adjuvant Therapy in Melanoma. N Engl J Med (2017) 0.94
Use of Liver Imaging and Biopsy in Clinical Practice. N Engl J Med (2017) 0.94
Anti-tissue transglutaminase antibodies from celiac patients are responsible for trophoblast damage via apoptosis in vitro. Am J Gastroenterol (2010) 0.94
Helicobacter pylori and extragastric diseases. Helicobacter (2014) 0.94
Reliability of the "immersion technique" during routine upper endoscopy for detection of abnormalities of duodenal villi in patients with dyspepsia. Gastrointest Endosc (2004) 0.93
Emerging technologies in upper gastrointestinal endoscopy and celiac disease. Nat Clin Pract Gastroenterol Hepatol (2008) 0.93
Highly purified eicosapentaenoic acid as free fatty acids strongly suppresses polyps in Apc(Min/+) mice. Clin Cancer Res (2010) 0.92
Neurotrophic features of human adipose tissue-derived stromal cells: in vitro and in vivo studies. J Biomed Biotechnol (2011) 0.92
The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs (2009) 0.92
High prevalence of celiac disease in patients with lactose intolerance. Digestion (2005) 0.91
Direct visualization of intestinal villi by high-resolution magnifying upper endoscopy: a validation study. Gastrointest Endosc (2004) 0.91
Role of probiotics in patients with Helicobacter pylori infection. Helicobacter (2007) 0.91
Gut microbiota and metabolic syndrome. Intern Emerg Med (2013) 0.91
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity. Radiology (2011) 0.91